SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
JAGX reported Third Quarter 2026 results. The price and volatility reaction is pending.
JAGXearnings

Earnings reactions, page 2

Jaguar Health, Inc. (JAGX) Q3 FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue, net was $2.343 million for the third quarter of 2026, compared to $3.083 million for the third quarter of 2025 (GAAP).
  • Loss from operations was $6.023 million for the third quarter of 2026, compared to $7.238 million for the third quarter of 2025 (GAAP).
  • Non-GAAP Recurring EBITDA was a net loss of $5.032 million for the third quarter of 2026, compared to a net loss of $9.025 million for the third quarter of 2025 (non-GAAP).
  • Non-GAAP EBITDA was a net loss of $5.590 million for the third quarter of 2026, compared to a net loss of $9.025 million for the third quarter of 2025 (non-GAAP).
  • The Company reduced its outstanding debt balance by $10.1 million in the third quarter of 2026 (GAAP).

Guidance

  • The Company expects to file a New Drug Application (NDA) for crofelemer for MVID in mid-2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →